Immunome, Inc. IMNM 深 滬
已收盤 05-15 16:00:00 美东时间
20.88
-1.140
-5.18%
華盛通- 最 高21.62
- 今 開21.56
- 成交量 130.98万股
- 最 低 20.61
- 昨 收 22.02
- 總市值 23.65亿
- 52周最高 27.65
- 市盈率 靜 --
- 換手率 1.16%
- 52周最低 7.96
- 委 比 6.22%
- 總股本 1.13亿
- 歷史最高 63.78
- 量 比 1.35
- 振 幅 4.59%
- 歷史最低 2.09
- 每 手 1
- 風險率 5.90%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅257.14%！瑞杰金融上调InflaRx目标价至9美元，评级升至"强烈买入"
今日重点评级关注：瑞杰金融：上调InflaRx评级至"强烈买入"，目标价从7美元升至9美元；巴克莱：维持Orchestra BioMed Hldgs"超配"评级，目标价从12美元升至13美元
05-14 14:32
HC Wainwright & Co. Reiterates Buy on Immunome, Maintains $40 Price Target
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Immunome (NASDAQ:IMNM) with a Buy and maintains $40 price target.
05-13 19:11
Immunome Q1 EPS $(0.48) Beats $(0.57) Estimate
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.57) by 15.79 percent. This is a 7.69 percent increase over losses of $(0.52) per share from the same
05-13 05:05
Immunome Reveals Oral Presentation Of Phase 3 RINGSIDE Data At 2026 ASCO Annual Meeting
Immunome, Inc. ("Immunome") (NASDAQ:IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its global, Phase 3,
04-21 22:31
Immunome Director Philip Wagenheim Disposes of Common Shares Worth USD 1,335,000
Immunome Director Philip Wagenheim Disposes of Common Shares Worth USD 1,335,000 Immunome director Philip Wagenheim reported sales of 36,800 common shares on March 20, 2026. On March 23, 2026, he reported selling 28,200 common shares. After the reported transactions, Philip Wagenheim beneficially ow
03-24 09:24
Immunome Director Jean Jacques Bienaime Acquires Common Shares
Immunome Director Jean Jacques Bienaime Acquires Common Shares Jean Jacques Bienaime, a director, reported an acquisition of common shares of Immunome Inc. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative a
03-12 18:10
美股大行评级 | 7家上调，3家下调！CrowdStrike绩后大行评级现分歧；罗斯百货、塔吉特、Viking获多家大行上调目标价
今日重点评级关注：古根海姆：维持Dianthus Therapeutics"买入"评级，目标价从100美元升至200美元；HC Wainwright & Co.：维持Amylyx Pharmaceuticals"买入"评级，目标价从28美元升至34美元
03-05 13:56
Stephens & Co. Maintains Overweight on Immunome, Lowers Price Target to $30
Stephens & Co. analyst Sudan Loganathan maintains Immunome (NASDAQ:IMNM) with a Overweight and lowers the price target from $33 to $30.
03-04 22:02
Immunome: Q4 Earnings Insights
Immunome (NASDAQ:IMNM) reported its Q4 earnings results on Tuesday, March 3, 20...
03-04 05:46
Immunome Q4 EPS $(0.75) Misses $(0.58) Estimate
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.58) by 29.09 percent. This is a 41.41 percent increase over losses of $(1.28) per share from the
03-04 05:23
